Laird Norton Wetherby Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-1,687
| Closed | -$232K | – | 944 |
|
|
2024
Q2 | $232K | Sell |
1,687
-98
| -5% | -$13.5K | 0.01% | 786 |
|
|
2024
Q1 | $246K | Buy |
1,785
+24
| +1% | +$3.31K | 0.01% | 802 |
|
|
2023
Q4 | $232K | Sell |
1,761
-112
| -6% | -$14.8K | 0.01% | 807 |
|
|
2023
Q3 | $211K | Buy |
+1,873
| New | +$211K | 0.01% | 803 |
|
|
2023
Q1 | – | Sell |
-1,841
| Closed | -$220K | – | 923 |
|
|
2022
Q4 | $220K | Buy |
+1,841
| New | +$220K | 0.01% | 773 |
|
|
2021
Q4 | – | Sell |
-2,155
| Closed | -$207K | – | 926 |
|
|
2021
Q3 | $207K | Sell |
2,155
-123
| -5% | -$11.8K | 0.01% | 831 |
|
|
2021
Q2 | $222K | Sell |
2,278
-20
| -0.9% | -$1.95K | 0.01% | 817 |
|
|
2021
Q1 | $224K | Buy |
+2,298
| New | +$224K | 0.02% | 708 |
|
|
2020
Q4 | – | Sell |
-2,199
| Closed | -$211K | – | 890 |
|
|
2020
Q3 | $211K | Buy |
2,199
+365
| +20% | +$35K | 0.02% | 631 |
|
|
2020
Q2 | $223K | Buy |
+1,834
| New | +$223K | 0.02% | 608 |
|